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Introduction
The control of type 1 diabetes is a widely studied and experimented research field. Previously published control methods are diverse, using different routes of insulin administration and glucose measurement. Since the 1970s, the closed-loop artificial endocrine pancreas has been heralded as the solution (as reviewed in Bequette 1 ). While no commercial product currently exists, the systems in current clinical use that are likely to constitute the components of an extracorporeal artificial pancreas are the continuous subcutaneous insulin infusion (CSII) pump and a continuous glucose measurement (CGM) device. Advanced control algorithms and methods to "close the loop" have also been widely studied (as reviewed elsewhere [2] [3] [4] ), despite early and ongoing limitations in sensors and pumps. Currently, the use of open-loop CGM and/or CSII has resulted in, at best, a modest clinical advantage over conventional methods of insulin administration or multiple daily injection (MDI) (as reviewed elsewhere 5, 6 ). Additionally, these systems are only used by a small population of type 1 diabetic patients because of high upfront costs, costs of consumables, complexity, and the extensive health care infrastructure and support required. The prevalence of CSII use is as low as 2% of the type 1 diabetes population in the United Kingdom and up to 15-20% elsewhere and in the United States. 7 Hence, there is a more practical and urgent need to address the large majority of the type 1 diabetes population using conventional glucose measurement, i.e., self-monitoring blood glucose (SMBG), and insulin administration, i.e., MDI methods, and for whom current conventional or intensive therapies are failing to deliver recommended levels of glycemic control. 8 In the United States, over 50% of diagnosed diabetics aged 20-64 are deemed "out of control. 9 " The higher accuracy of bedside capillary blood glucose meters 10, 11 and the latest insulin analogues for MDI therapy, 12 coupled with better control methods, have the potential to provide better care to the majority of outpatient or ambulatory type 1 diabetics than currently observed. Such techniques must necessarily be simple to implement to ensure broad clinical uptake by the diabetes population.
This study reports the development of a system model of the type 1 insulin-glucose regulatory system and its identification on a virtual patient cohort. The models utilized have several novel and unique features. In particular, the insulin model used is unique and captures the insulin kinetics of multiple insulin types in a single pharmacokinetic model for all shared physiological spaces. The pharmacodynamic model used has not been reported previously but bears components of a similar nature to other such models used in this field due to the need to capture similar physiology. This study is the basis for a novel model-based application to develop a simple and practical adaptive method for clinical glycemic control of type 1 diabetes using multiple daily injection and self-monitoring blood glucose measurements. In addition, the modeling of long-term clinical outcomes of glycemic control and their corroboration against clinical expectations and studies are explored further in a subsequent in silico simulation on a virtual patient cohort, which is also reported in this issue. Later, the complex interaction of all quantifiable errors in protocol application is investigated in a Monte Carlo study to test the robustness of the developed protocol in effectiveness and safety. 13 
Model Development
The system model shown in Equation (1) is an evolution of the model of Chase et al. 14 and Wong et al.
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(1)
where G(t) is plasma glucose concentration (mmol/liter), CNS is central nervous system glucose uptake (mmol/ liter·min), EGP 0-G is endogenous glucose production extrapolated to zero plasma glucose concentration (mmol/ liter·min), p G is glucose effectiveness (min -1 ), S I is insulin sensitivity (liter/min·mU), Q(t) is interstitial (effective) insulin concentration (mU/liter), RGC(t) is renal glucose clearance (mmol/liter·min), and P(t) is meal plasma glucose rate of appearance (mmol/liter·min).
This glucose model differs mathematically from the model developed by Chase et al. 14 and Wong et al. 15 in removal of insulin effect saturation and addition of the renal glucose clearance rate, RGC(t). These two studies were done on highly dynamic, critically ill patients with high effective insulin resistance who were treated with intravenous insulin doses. Removal of the insulin effect saturation was deemed suitable for modeling more compliant, insulin-sensitive and stable type 1 diabetes patients treated with subcutaneously administered insulin. (2) where RGC(t) is renal glucose clearance (mmol/liter·min), GFR is glomerular filtration rate (liter/min), G(t) is plasma glucose concentration (mmol/liter), RGT is renal glucose threshold (mmol/liter), V p is glucose distribution volume (liter/kg), and m b is body mass (kg).
Referring to Equation (2), the renal glucose clearance rate, RGC(t), models glucose removal by the kidney above the renal glucose threshold, RGT, using a linear relationship proportional to the glucose concentration above RGT and the glomerular filtration rate, GFR. From the study by Johansen and colleagues, 16 this linear approximation is acceptable. Linear models have also been used in AIDA 17 by Lehmann et al. 18 and by Arleth et al.
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Insulin absorption from subcutaneous injection or infusion has been widely studied since Binder. 20 A novel, compartmental model of subcutaneous insulin absorption kinetics specifically developed for diabetes decision support has been presented. 21, 22 The model accounts for the volume and concentration dependence of regular human insulin absorption and models the absorption kinetics of six insulin types, including monomeric insulin and insulin glargine. Additionally, insulin injected or infused subcutaneously or intravenously can also be modeled. A schematic of the model adapted from Wong and colleagues 22 is shown in Figure 1 . This model is used in this study, which is the first application of the developed model in the control of type 1 diabetes.
Modeling of the meal glucose rate of appearance (R a ), including digestion, absorption, and transport of glucose, is a complex process not widely studied. 23 Meal carbohydrate amount and type are the main factors affecting meal glucose R a or P(t) in Equations (1) and (6). 24, 25 However, clinical models of glucose R a almost universally accept input of meal glucose amount only. 18, 26 The minimal models of meal glucose R a by Worthington 31 and Lehmann et al. 17, 18 form the basis of the model used in this study. Referring to Figure 2 and Equations (3)-(5), the model consists of two compartments for the stomach and gut, with linear gastric emptying and gut-absorption rates to describe the plasma glucose R a in Equation (6). Another simplification is the expression of meal carbohydrate content (in grams) as equivalent to the same mass of glucose monosaccharide regardless of the meal carbohydrate type. 23 Again, such meal data are typically unavailable in a clinical setting. As such, the complex digestion processes, such as the hydrolysis of polysaccharides, are assumed linear and lumped into the simplified processes given earlier. (6) where STO(t) is mass of carbohydrate/glucose in the stomach (g), GUT(t) is mass of carbohydrate/glucose in the gut (g), GABS is gut carbohydrate/glucose absorption rate (g/min), GABS max is maximum gut carbohydrate/glucose absorption rate (g/min), k 6 is carbohydrate/glucose gastric emptying rate (min -1 ), k 7 is carbohydrate/glucose gut-absorption rate (min -1 ), u CHO (t) is meal carbohydrate/ glucose input (g/min), P(t) is meal plasma glucose rate of appearance (mmol/liter·min), V p is glucose plasma distribution volume (liter/kg), and m b is body mass (kg).
Worthington 31 found that the one-compartment model with time delay had the smallest fitting error. However, this result was obtained with a model fit to plasma glucose data and is dependent on the model of glucose kinetics used. Lehmann and colleagues 18 used a "complex" function to describe the gastric emptying rate from the stomach compartment. This study used a linear transport rate, k 6 , while the glucose input into the stomach compartment, u CHO (t), is described by a delta function. Similar to the saturable gastric emptying rate of Lehmann et al., 18 this study incorporated a saturable gut-absorption rate, GABS max . Saturable gut absorption has been postulated by Korach-Andre and colleagues 32 in experiments using relatively large starch meals. However, this difference is likely to be small considering the minimal nature of both models. Referring to Figure 3 , the effective gut-absorption rate is shown as a function Figure 1 . Structure of the subcutaneous insulin absorption kinetic model. The model is characterized by a common hexameric state compartment for regular insulin (RI), neutral protamine Hagedorn (NPH) insulin, and lente insulin (xh), whereas those for insulins glargine and ultralente (xh,ulen and xh,gla) are separate. A crystalline state compartment for NPH (cNPH), lente (clen), and ultralente (culen) insulins and a precipitate compartment for insulin glargine (pgla) model these protraction mechanisms. All insulin flows through a common a dimeric-monomeric state compartment (x dm ), interstitium compartment (xi), and finally into the plasma (I). Adapted from Wong et al. 22 of the mass of carbohydrate/glucose in the GUT compartment. Addition of the saturable term GABS max effectively makes the gut absorption rate nonlinear as a function of the amount of carbohydrate in the gut. This dynamic is similar to that of the nonlinear three-compartment model of Dalla Man et al., 26 which consists of dual stomach compartments with a nonlinear gastric emptying rate with four identified parameters. The nonlinear gastric emptying term is described by a hyperbolic tangent function as a function of the proportion of the consumed carbohydrate remaining in the stomach. There is no saturation term considered for large, absolute meals.
Referring to Table 1 , the values of patient-independent model population constants are a priori identified from literature. The renal glucose threshold, RGT, has been shown to vary considerably in type 1 diabetes,
but median values of 10 mmol/liter have been widely reported. The glucose distribution volume, V p , is taken to be 0.22 liter/kg, the same value used by Lehmann et al. 18 The glomerular filtration rate, GFR, is taken as 0.12 liter/ min or 120 ml/min, which reflects the average adult GFR of 125 ml/min. 33 In a study by Dalla Man et al., 34 the maximum meal R a (R a meal ) was ~8-9 mg/kg·min after an oral dose of 1 g/kg glucose. In the study by Korach-Andre et al., 32 the exogenous meal R a (R a exo ) was approximately 7-9 mg/kg·min for a meal of 4 g/kg of starch (~4.4 g/kg glucose). Despite the fourfold increase in glucose load, the maximum R a remains at ~9 mg/kg·min or ~0.72 g/min for an average adult. In a study by Noah et al., 35 a higher figure still of 11 mg/kg·min was reported in a porcine model. The maximum value of the rate of gut absorption is taken as 1.1 g/min using the Noah et al. 35 study as a basis, assuming a 100-kg body weight.
The proportion of glucose lost to first-pass splanchic uptake is still being debated, with proportions from negligible 36, 37 to as high as 30% reported in some studies. 38 As there will be no tracer data in the intended application of the model, negligible losses from first-pass splanchnic sequestration and complete absorption are assumed for simplicity 39 with complete absorption of meal glucose. The values of k 6 and k 7 are optimized using nonlinear least squares to model-independent, mixed-meal tracer glucose R a data 34 (results not shown).
The values of CNS, EGP 0-G , and p G are derived from results of studies done by Del Prato et al. 40, 41 Like the minimal model of Bergman and colleagues, 42 the model is unable to differentiate noninsulin-mediated glucose uptake from production, which is lumped into a linear relationship with glucose. Referring to Figures 4 and 5 , total body glucose uptake (TBGU) and hepatic glucose production (HGP) data described elsewhere 40, 41 are used to identify CNS, EGP 0-G , and p G . Data at glucose exceeding the approximate RGT of 10 mmol/liter are ignored to eliminate the need to evaluate renal glucose clearance, RGC, and associated errors. Under fasting and insulinopenic conditions, the P(t) and S I G(t)Q(t) terms of Equation (1) can be further eliminated. By the linear 
GABS(t) = min(k 7 GUT(t) ,GABS max )
u CHO (t) Figure 3 . Qualitative plot of the effective gut absorption rate as a function of the mass of carbohydrate/glucose in the GUT compartment. While the process of gastric emptying is linear, addition of the saturable gut absorption term, GABSmax, of 1.1 g/min effectively makes the process of gut absorption, and hence meal glucose R a , nonlinear. At low glucose levels in the gut, the effective gut absorption rate is 0.0097 liter/min.
GUT (g) Effective gut absorption rate (liter/min)
definition of the effect of hyperglycemia on TBGU, CNS can then be derived as the "virtual" y intercept of the linear TBGU curve. The term "virtual" is used, as no glucose uptake is theoretically possible at zero glucose. The central nervous system glucose uptake CNS is saturated at 3.3 mmol/liter and is relatively insensitive to insulin and glucose. 43, 44 At euglycemia, CNS accounts for ~70% of all noninsulin-mediated glucose uptake, 45 and this proportion is likely to increase with hypoglycemia. Hence, use of the term CNS for the virtual y intercept of the linear TBGU curve is justified.
Similarly, by the linear definition of the effect of hyperglycemia on HGP, EGP 0-G is the y intercept of the linear HGP curve and p G is the slope of the combined TBGU and HGP curve. Hence, p G is similar to the minimal model glucose effectiveness, S G , but is defined under conditions of insulinopenia or subbasal insulin rather than basal insulin. 46 Unlike the minimal model, the insulin model in this study models the absolute insulin concentration, not insulin concentration above basal. In type 1 diabetes, conditions of basal insulin are not necessarily met all the time. Using data from Del Prato and colleagues 41 for an insulinopenic normal cohort (Figure 4 . 46 Using data of Del Prato et al. 40 for an insulin-dependent diabetes mellitus (IDDM) cohort under basal insulin (Figure 5) , values of CNS = 1.7 mg/kg·min, EGP 0-G = 3.0 mg/kg·min, and p G = 0.006 min -1 were obtained. Hence, p G of the normal, insulinopenic cohort 41 is similar to the IDDM cohort under basal insulin. 40 This result is logical, as S G is decreased in IDDM, 46 whereas basal insulin increases S G , either by increased glucose uptake 44 or by suppression of endogenous glucose production. 41 In IDDM, the p G obtained is also approximately half that of published S G values of ~0.013 min -1 . 46 One explanation is the elimination of data at high glucose concentrations from the p G analysis, which, if unaccounted for, would include the effect of urinary glucose excretion, thereby increasing the "effective" glucose uptake. From this investigation, it can be deduced that for an IDDM cohort under conditions of insulinopenia, p G must have an upper bound of 0.006 min -1 , which is assumed in this study. 18 and can simulate glycemic levels for any insulin or meal stimuli over a period of 1 day. Patient data (n = 40) for this study were obtained from sample diabetes case scenarios available with AIDA on-line 2 . Referring to Table 2 , each patient case is unique in body weight, meals/carbohydrates consumed, and insulin treatment. Each patient also has unique clinical variables of hepatic and peripheral insulin sensitivity, glucose renal threshold, and glomerular filtration rate. Hence, the AIDA on-line 2 cohort represents a broad range of patients and possible clinical behavior. To retrieve blood glucose, plasma insulin, and meal glucose absorption rates from AIDA on-line 2 , the "Advanced" display is selected to output data in text format. A sample of these data is shown in Figure 6 .
Simulation Method
For in silico simulation, the virtual patient method is used. 50, 51 This method has been utilized to develop effective glycemic control protocols by simulating the physiological glycemic response to glucose and insulin stimuli. [50] [51] [52] The glycemic responses are generated with patient-specific S I (t) profiles derived from retrospective data. This clinically validated method 50 enables extensive simulations to be performed in a short time for rapid development and testing of any control methodology.
In silico simulation was performed using MATLAB ® (The Mathworks, Natick, MA) implemented on a personal computer notebook (Pentium M 1.7 GHz).
To obtain the retrospective S I (t) patient data profiles, the model is first fitted to data using the linear and convex, integral-based parameter identification method. 53 Equation (1) can be expressed in a generic integral form [Equation (7)] for period t i-1 to t i , which can then be rearranged into a set of linear equations as shown in Equation (9). All quantities in Equation (7) are modeled and, as such, are known except for G(t).
AIDA on-line 2 uses a first-order Euler integration method with a 15-minute step size to solve the plasma glucose model equation. 54 To determine G(t) to solve Equation (7), AIDA on-line 2 glucose data are interpolated linearly to obtain a piecewise linear G(t) function [Equation (8)].
The t i -t i-1 time interval for the optimization of S I (t) is chosen arbitrarily as 10 minutes. Equation (8) is solved using a proprietary MATLAB linear solver. Referring to Figure 7 and Equations (9) and (10), a stepwise, timevariant S I (t) with a 10-minute step interval is obtained. A proprietary MATLAB numerical ODE solver is used to solve the model equations with a 1-minute time step. Biphasic insulin preparations are treated as in AIDA with the insulin response assumed to be a superposition of the individual components of the preparation. 18 This is an acknowledged simplification considering the large variety and lack of data on such preparations.
The numerical solution to the model equations forms the in silico simulation tool. With the set of 40 virtual patient S I (t) profiles, any meal or subcutaneous insulin input and its effect on glycemia can be simulated with the assumption that S I is independent of the inputs administered, i.e., the virtual patient. This opens the possibility of simulating any glycemic control protocol, even current clinical methods. [55] [56] [57] An initial validation would be to replicate long-term glycemic control outcomes, e.g., hemoglobin A1c.
Results
To gauge the model fit to data, absolute and absolute percentage errors of the G(t) model fit to the AIDA online 2 patient data cohort are shown in Tables 3 and 4. In Table 3 , per patient errors are shown, whereas total errors over the entire cohort are shown in Table 4 . A sample G(t) fit is also shown in Figure 8 .
From Table 3 , the per patient median (95% range) absolute percentage error in G(t) is 1.24% (0.09-4.85%), which translates into a per patient absolute error in G(t) of 0.11 mmol/liter (0.01-0.43 mmol/liter). Over the entire cohort the figures are 1.33% (0.08-7.20%) and 0.12 mmol/ liter (0.01-0.56 mmol/liter), which are similar. The errors reported are extremely low and within the measurement errors of clinical methods of glucose measurement in current use. This shows that the model and S I identification method is capable of capturing all patient G(t) dynamics, which will produce a more physiologically accurate simulation.
Conclusions
An in silico simulation tool was presented that utilizes an extended model of glucose kinetics, a simple glucose rate of appearance model, and the novel application of a subcutaneous insulin pharmacokinetic model. Models are identified to a physiological cohort of type 1 diabetes virtual patients. To corroborate the approach initially, an in silico simulation with data from the patient cohort using the virtual patient simulation method is planned. 
